Focus areas / Depression 12 Sep, 2024 Brintellix® Achieving higher rates of treatment success and satisfaction with Brintellix®1,2 12 Sep, 2024 Brintellix® Brintellix® improves overall functioning with the greatest improvement observed at 20mg1 12 Sep, 2024 Brintellix® Brintellix® pharmacokinetic profile1 12 Sep, 2024 Brintellix® Brintellix® is generally well tolerated †1 12 Sep, 2024 Brintellix® Brintellix® may be increased to 20 mg after Week 1 without compromising tolerability1 12 Sep, 2024 Brintellix® Clinical benefits of early use of Brintellix ® 20 mg 1 12 Sep, 2024 Brintellix® Brintellix® may be increased up to 20 mg without compromising patients' tolerability1 12 Sep, 2024 Brintellix® The efficacy of Brintellix® increases with increasing dose response 17 Jul, 2024 Brintellix® Differences in dose-response relationships among commonly used antidepressants 17 Jul, 2024 Brintellix® Brintellix® efficacy increases with increasing dose†1,2 09 Apr, 2024 Brintellix® Brintellix® showed clinically meaningful reductions in emotional blunting† in patients with MDD with a partial response to previous SSRIs/SNRIs‡1,3 09 Apr, 2024 Brintellix® Brintellix® improved motivation and energy in patients with MDD1 09 Apr, 2024 Brintellix® Brintellix® reduced emotional blunting in patients with MDD1 09 Apr, 2024 Brintellix® Brintellix® effectively improved overall functioning in patients with MDD with a partial response to previous SSRIs/ SNRI treatment 09 Apr, 2024 Brintellix® Increasing doses of SSRIs were associated with a linear increase in adverse events, but response rates were not 08 Feb, 2024 Brintellix® Prevalence of emotional blunting across commonly used antidepressants Load More GO TO Product Home
